DcR1 Antibody
| Code | Size | Price |
|---|
| PSI-2179-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-2179-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
DcR1 Antibody: LIT, DCR1, TRID, CD263, TRAILR3, TRAIL-R3, DCR1-TNFR, LIT, UNQ321/PRO366, Tumor necrosis factor receptor superfamily member 10C, Decoy TRAIL receptor without death domain, DcR1
Application Note:
DcR1 antibody can be used for detection of DcR1 by Western blot 0.5 μg/mL. An approximate 65 kDa band can be detected. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
DcR1 Antibody: Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumor cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL. Two decoy receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT and DcR2/TRAIL-R4/TRUNDD. DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines. Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis.
Background References:
- Pan G; O'Rourke K; Chinnaiyan et al.. The receptor for the cytotoxic ligand TRAIL. Science; 1997;276:111-113
- Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8
- Sheridan JP, Marsters SA, Pitti RM, et al. A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21
- Degli-Esposti MA, Smolak PJ, Walczak H, et al, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186(7):1165-70
Buffer:
DcR1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
DcR1 antibody was raised against a peptide corresponding to amino acids in a extracellular domain of human DcR1 precursor.
The immunogen is located within amino acids 140 - 190 of DcR1.
The immunogen is located within amino acids 140 - 190 of DcR1.
NCBI Gene ID #:
8794
NCBI Official Name:
tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain
NCBI Official Symbol:
TNFRSF10C
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
65 kDa
Protein Accession #:
AF012536
Protein GI Number:
2338421
Purification:
DcR1 Antibody is DEAE purified.
Research Area:
Apoptosis
Swissprot #:
O14798
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | DcR1 Peptide | PSI-2179P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|